The effect of benralizumab on inflammation in severe asthma: a real-life analysis

Background: Benralizumab is a monoclonal antibody treatment for severe eosinophilic asthma (SEA). Few studies investigated its role in airway inflammation and its correlation with lung function. Objectives: The aim of the present study is to assess its effect after 1 year of treatment, focusing on a...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Respiratory Disease
Main Authors:	Dina Visca, Francesco Ardesi, Martina Zappa, Sarah Grossi, Patrizia Pignatti, Marco Vanetti, Laura Pini, Giovanni Sotgiu, Rosella Centis, Giovanni Battista Migliori, Antonio Spanevello
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-12-01
Online Access:	https://doi.org/10.1177/17534666241304685